NCT07315373

Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia

The FIND Study: A Dose-finding Study to Identify the Optimal Dose of Zanubrutinib in Adults With Immune Thrombocytopenia

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to find the best dose of zanubrutinib when used together with high-dose dexamethasone for adults who are newly diagnosed with primary immune thrombocytopenia (ITP), and to learn how safe and effective this combination treatment is.

Conditions

• Immune Thrombocytopenia

Interventions

Type	Name	Description
DRUG	Zanubrutinib 80mg/d	Zanubrutinib: 80 mg taken orally once daily for 26 weeks
DRUG	High dose dexamethasone	Dexamethasone: 40 mg taken orally once daily for 4 consecutive days at the beginning of treatment. A second identical 4-day course may be repeated after 2 weeks if an adequate initial platelet response is not achieved.
DRUG	Zanubrutinib 160mg/d	Zanubrutinib: 160 mg taken orally once daily for 26 weeks
DRUG	Zanubrutinib 240mg/d	Zanubrutinib: 240 mg taken orally once daily for 26 weeks

Timeline

• Start date: 2025-12-25
• Primary completion: 2028-12-30
• Completion: 2029-06-30
• First posted: 2026-01-02
• Last updated: 2026-01-02